钠葡萄糖协同转运蛋白2抑制剂达格列净改善内皮素A受体拮抗剂齐泊腾坦的液体潴留效应
在4%盐负荷WKY大鼠中,齐泊腾坦降低第7天血细胞比容并增加体重;联用达格列净可预防齐泊腾坦引起的血细胞比容变化和体重增加,支持开展临床研究评估二者联用在CKD患者中的疗效与安全性。
要点
- 齐泊腾坦30、100、300 mg/kg/day组第7天血细胞比容均低于溶媒组。
- 齐泊腾坦100 mg/kg/day联用达格列净3 mg/kg/day可预防血细胞比容变化。
- 联用达格列净可预防齐泊腾坦驱动的体重增加。
核心结论
- 内皮素A受体拮抗剂与SGLT2抑制剂联用可预防内皮素A受体拮抗剂诱导的液体潴留,支持开展临床研究评估齐泊腾坦与达格列净联用在CKD患者中的疗效与安全性。
研究设计与样本
- 在4%盐负荷WKY大鼠中进行的实验研究:先确定齐泊腾坦(30、100或300 mg/kg/day)对血细胞比容和体重的影响;再评估齐泊腾坦(30或100 mg/kg/day)单用或联用达格列净(3 mg/kg/day)对血细胞比容和体重的影响。
主要发现
- 第7天血细胞比容在齐泊腾坦组低于溶媒组:齐泊腾坦30 mg/kg/day组43%(标准误1)、100 mg/kg/day组42%(1)、300 mg/kg/day组42%(1) vs 溶媒组46%(1),P < .05。
- 所有齐泊腾坦组体重较溶媒组在数值上更高。
- 齐泊腾坦100 mg/kg/day联用达格列净3 mg/kg/day 7天预防了血细胞比容变化:联用组45%(1) vs 溶媒组46%(1),P = .44。
- 齐泊腾坦100 mg/kg/day联用达格列净3 mg/kg/day预防了齐泊腾坦驱动的体重增加:基线校正体重变化为-3.65 g,P = .15。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endothelin A receptor antagonists (ETARA) slow chronic kidney disease (CKD) progression but their use is limited due to fluid retention and associated clinical risks. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) cause osmotic diuresis and improve clinical outcomes in CKD and heart failure. We hypothesized that co-administration of the SGLT2i dapagliflozin with the ETARA zibotentan would mitigate the fluid retention risk using hematocrit (Hct) and bodyweight as proxies for fluid retention. METHODS: Experiments were performed in 4% salt fed WKY rats. First, we determined the effect of zibotentan (30, 100 or 300 mg/kg/day) on Hct and bodyweight. Second, we assessed the effect of zibotentan (30 or 100 mg/kg/day) alone or in combination with dapagliflozin (3 mg/kg/day) on Hct and bodyweight. RESULTS: Hct at Day 7 was lower in zibotentan versus vehicle groups [zibotentan 30 mg/kg/day, 43% (standard error 1); 100 mg/kg/day, 42% (1); and 300 mg/kg/day, 42% (1); vs vehicle, 46% (1); P < .05], while bodyweight was numerically higher in all zibotentan groups compared with vehicle. Combining zibotentan with dapagliflozin for 7 days prevented the change in Hct [zibotentan 100 mg/kg/day and dapagliflozin, 45% (1); vs vehicle 46% (1); P = .44] and prevented the zibotentan-driven increase in bodyweight (zibotentan 100 mg/kg/day + dapagliflozin 3 mg/kg/day = -3.65 g baseline corrected bodyweight change; P = .15). CONCLUSIONS: Combining ETARA with SGLT2i prevents ETARA-induced fluid retention, supporting clinical studies to assess the efficacy and safety of combining zibotentan and dapagliflozin in individuals with CKD.
引用
- Veenit V, Heerspink HJL, Ahlström C, et al. The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan. Nephrol Dial Transplant. 2023. PMID: 37102226. doi:10.1093/ndt/gfad078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。